Low C-Peptide Levels: What They Mean and When to Worry

Key Takeaways

• What low C-peptide indicates: Significantly reduced or absent insulin production from pancreatic beta cells; the most common causes are Type 1 diabetes, LADA, and advanced Type 2 diabetes with beta cell exhaustion.
• Clinical threshold: Below approximately 0.2 nmol/L (0.6 ng/mL) fasting is associated with substantial insulin deficiency; below the lower reference limit (0.5 ng/mL fasting) may indicate reduced beta cell reserve even without frank deficiency.
• Assay sensitivity matters: Ultrasensitive assays can detect very small amounts of residual C-peptide that standard assays classify as undetectable — a distinction with clinical significance.
• Causes are distinct: Type 1 autoimmune destruction, LADA, advanced Type 2 beta cell exhaustion, and factitious hypoglycemia all produce low C-peptide through different mechanisms, requiring different clinical responses.
• Key confounder: Renal impairment raises C-peptide; low C-peptide in a patient with chronic kidney disease therefore represents genuinely low production, making the result more clinically significant in that context.
• Assay standardization: Absolute values vary between platforms; serial measurements should use the same assay for valid longitudinal comparison.
• Clinical action: Very low or undetectable C-peptide in an individual without an established Type 1 diagnosis warrants autoantibody testing and provider evaluation before therapeutic decisions are made.

What Low C-Peptide Levels Mean

C-peptide (connecting peptide) is a 31-amino-acid chain the pancreas releases in a one-to-one molar ratio with insulin during proinsulin processing. Because it is co-secreted with insulin and reflects total endogenous insulin production, a low C-peptide value directly indicates that the beta cells are not producing adequate insulin. Jones and Hattersley, in a 2013 review in Diabetic Medicine, established C-peptide as the clinical standard for endogenous insulin measurement, noting that low values represent a specific, interpretable signal about pancreatic beta cell function rather than simply an abnormal number.

The clinical significance of a low C-peptide value depends on three things: the absolute level (how low is it?), the setting (what is the accompanying glucose?), and the trajectory (how quickly did it get there?). A fasting serum C-peptide below approximately 0.2 nmol/L is generally associated with clinically meaningful insulin deficiency. Values between the lower reference limit (approximately 0.5 ng/mL) and the deficiency threshold may reflect reduced beta cell reserve without frank insufficiency.

C-Peptide Reference Ranges and Low-Value Thresholds

Leighton and colleagues, in their 2017 practical review in Diabetes Therapy, provide the standard fasting reference interval and the thresholds used in clinical interpretation.

• Adults (fasting serum) — population reference interval: 0.5–2.0 ng/mL (0.17–0.83 nmol/L)
• Borderline low (fasting): Below 0.5 ng/mL (0.17 nmol/L); may indicate reduced beta cell reserve; requires clinical context
• Significantly low (fasting): Below approximately 0.2 nmol/L (0.6 ng/mL); associated with substantial beta cell loss and likely insulin deficiency
• Undetectable (standard assay): Below assay lower limit of detection; in long-standing Type 1 diabetes, this is expected; ultrasensitive assays may detect trace production
• Urine C-peptide creatinine ratio (UCPCR) — deficiency threshold: Below 0.2 nmol/mmol is associated with significant insulin deficiency; above this level suggests at least some preserved beta cell function

Reference ranges vary by laboratory and individual. The values above represent typical population-derived reference intervals and are not universal diagnostic thresholds. Your provider will interpret your specific result alongside symptoms, medical history, and other test findings.

What Causes Low C-Peptide Levels

Low C-peptide is the biochemical marker of reduced or absent insulin production. The mechanism varies considerably between the clinical scenarios that produce it.

Type 1 diabetes: autoimmune beta cell destruction

In Type 1 diabetes, T-cell-mediated immune destruction progressively eliminates pancreatic beta cells. C-peptide production falls as beta cell mass declines, reaching very low or undetectable levels in most individuals with established Type 1 disease. Sims and colleagues, in a 2019 Diabetes Care analysis of TrialNet samples, documented that detectable proinsulin and C-peptide persist across T1D diagnosis, including the period around the time of clinical onset. Besser, Shields, and colleagues (with Ludvigsson), in a 2013 paper in Diabetes Care, characterized the C-peptide fall after Type 1 diagnosis using mixed-meal tolerance testing, showing that the rate of beta cell loss varies between individuals and that early C-peptide measurement at diagnosis can inform prognosis. Oram and colleagues, using an ultrasensitive assay in a 2015 Diabetes Care study, showed that most individuals with long-standing Type 1 diabetes retain measurable C-peptide (insulin microsecretors) even when standard clinical assays classify it as absent — a finding with clinical relevance for glycemic stability and complication risk.

LADA (latent autoimmune diabetes in adults)

LADA presents clinically as Type 2 diabetes but involves autoimmune beta cell destruction, producing a C-peptide trajectory that starts preserved and then declines more rapidly than expected for Type 2 alone. Maddaloni, Bolli, and Frier, in a 2022 review in Diabetes, Obesity and Metabolism, described how C-peptide with autoantibody testing differentiates LADA from Type 2 — a distinction with significant treatment implications. A person diagnosed with Type 2 diabetes who develops unexpectedly rapid beta cell decline reflected in falling C-peptide warrants autoantibody testing to evaluate for LADA.

Advanced Type 2 diabetes with beta cell exhaustion

In the natural history of Type 2 diabetes, sustained demand for excess insulin production can gradually exhaust beta cell capacity. C-peptide levels that were initially elevated during the compensatory insulin resistance phase may decline over years to decades, eventually reaching low or near-absent values as the pancreas can no longer compensate. Lin, McCrimmon, and Pearson, in a 2025 review in Diabetic Medicine, describe how declining C-peptide signals insulin dependence in Type 2 diabetes. Lee, Bray, and Morley, in a 1996 study in Endocrine Practice, demonstrated that low stimulated C-peptide is a criterion for initiating insulin therapy in adults with Type 2 diabetes — making C-peptide measurement a direct guide to treatment decisions at this stage.

Factitious hypoglycemia: exogenous insulin and the C-peptide clue

One of the most important clinical applications of C-peptide is in the hypoglycemia workup. When blood glucose is low, the pattern of C-peptide level determines the biochemical diagnosis. Insulinoma produces hypoglycemia with high C-peptide (endogenous insulin excess). Exogenous insulin injection produces hypoglycemia with low or undetectable C-peptide, because injected insulin contains no C-peptide and suppresses endogenous secretion. Rubenstein, Kuzuya, and Horwitz, in a foundational 1977 paper in Archives of Internal Medicine, established C-peptide as a central tool in hyperinsulinism evaluation. Oram and colleagues, in a 2014 paper in Diabetologia, described fasting and stimulated C-peptide in long-standing Type 1 diabetes, demonstrating that most patients retain low-level beta-cell function detectable by ultrasensitive assay even when standard testing suggests complete exhaustion.

The Clinical Significance of Very Low C-Peptide

Low C-peptide is not a passive finding. Several clinical outcomes are meaningfully associated with the degree of beta cell loss it reflects.

Glycemic instability and hypoglycemia risk

Residual C-peptide secretion, even at low levels, provides a buffer against glycemic extremes in Type 1 diabetes. Beta cells that still produce some insulin respond to physiological glucose signals in ways that exogenous insulin cannot fully replicate. Lachin and colleagues, in a 2014 Diabetes analysis of DCCT/EDIC data, documented that residual C-peptide secretion in Type 1 diabetes was associated with better glycemic control and lower microvascular risk — including retinopathy and nephropathy. The absence of residual C-peptide (complete beta cell loss) correlates with greater glycemic variability and an increased risk of hypoglycemic episodes.

Disease trajectory and prognosis

C-peptide level at diagnosis of Type 1 diabetes and its rate of decline predict future glycemic outcomes. Davis and colleagues, in a 2015 Diabetes Care T1D Exchange analysis, showed that higher C-peptide at Type 1 diabetes diagnosis (including older age at onset) was associated with better endogenous insulin function and glycemic control, measured by HbA1c, over follow-up. An individual who retains more beta cell function at diagnosis has a more favorable short-term glycemic trajectory, reinforcing the clinical value of measuring C-peptide — and not just glucose — at the time of diagnosis.

Beta cell stress and proinsulin processing

In states of high demand on remaining beta cells, proinsulin is released before complete processing, altering the ratio of proinsulin to C-peptide. Sims and colleagues, in a 2019 paper in Diabetes Care, documented that proinsulin secretion persists and rises relative to C-peptide across the first years after Type 1 diagnosis, indicating increasing beta cell stress even before total C-peptide falls to undetectable levels. This ratio provides additional information about the trajectory of beta cell health beyond the absolute C-peptide value.

Factors That Affect Low C-Peptide Interpretation

Several factors can make a C-peptide value appear lower or higher than the true beta cell output.

• Assay platform — affects absolute values: Kabytaev, Maddaloni, and Ferm, in a 2026 paper in Diabetes, Obesity and Metabolism, emphasized the need for C-peptide measurement standardization across platforms. A value that is borderline low on one platform may fall within range on another. Serial measurements for tracking decline should use the same assay at the same laboratory.
• Renal impairment — raises values: The kidney clears C-peptide; chronic kidney disease prolongs its half-life and raises measured levels. A low C-peptide result in a patient with impaired renal function is therefore even more significant — the reduced clearance advantage has been lost, meaning the true beta cell output is genuinely low.
• Diabetes duration — expected decline in Type 1: Davis and colleagues, in a 2015 Diabetes Care T1D Exchange analysis, showed that C-peptide detectability falls with both younger age of onset and longer duration of Type 1 diabetes. Undetectable C-peptide in someone with 20-year Type 1 diabetes is an expected finding; the same result in a patient newly diagnosed at age 45 is more clinically significant and warrants investigation.
• Fasting state: A low C-peptide result is only valid for comparison against fasting reference ranges if the patient was appropriately fasted (8–12 hours). A postprandial sample may show higher C-peptide, masking borderline low values.
• Stimulated vs. fasting testing: Besser and colleagues, in a 2013 paper in Diabetes Care, showed that fasting C-peptide may underestimate function relative to stimulated (mixed-meal) measurements in some individuals, particularly those with partial or slowly progressive beta cell loss. A stimulated test may reveal preserved secretory capacity not apparent from fasting levels alone.

How Low C-Peptide Is Tested and Confirmed

What type of sample is used

Standard testing uses a fasting venous blood draw processed to serum. A non-invasive alternative — the urine C-peptide creatinine ratio (UCPCR) — is validated for use in stable outpatients and avoids venipuncture. Wang and colleagues, in a 2019 paper in the Journal of Diabetes Research, documented the clinical implications of UCPCR across different diabetes types, confirming its utility for assessing insulin deficiency in a practical outpatient setting.

Fasting requirements and stimulated confirmation

An 8-to-12-hour fast is required for valid comparison against fasting reference ranges. When fasting C-peptide is borderline or when quantifying the maximum remaining secretory capacity matters, a stimulated test is ordered. The glucagon stimulation test — described by Madsbad and colleagues in 1981 in Acta Medica Scandinavica for assessing beta cell function — involves 1 mg IV glucagon with C-peptide measured 6 minutes later and remains a standard clinical tool for this purpose.

Timing and turnaround

Serum C-peptide results are typically available within 24 to 48 hours. Morning fasting is the standard timing for baseline measurements, as counter-regulatory hormone variation throughout the day can modestly affect values. Specimens should be processed or refrigerated within two hours of collection.

Which Biomarkers Are Worth Testing Alongside Low C-Peptide

Low C-peptide is rarely evaluated in isolation. A targeted set of companion markers provides the context needed to determine the cause and clinical implications.

• Glucose (fasting): The pairing of C-peptide and glucose is the core interpretive unit. Low C-peptide with high glucose is consistent with insulin deficiency; low C-peptide with low glucose is the pattern of exogenous insulin use or complete beta cell failure in a fasted state. Why test alongside C-peptide: C-peptide without glucose context cannot be fully interpreted.
• Hemoglobin A1c (HbA1c): Reflects average glycemic control over approximately 3 months. Together with C-peptide, it characterizes whether inadequate beta cell output is translating into poor glycemic control. Why test alongside C-peptide: Low C-peptide with elevated HbA1c is a straightforward insulin deficiency picture; low C-peptide with normal HbA1c may indicate well-compensated reduced function or measurement context issues.
• Insulin (fasting): Provides complementary information about insulin demand and peripheral sensitivity. Why test alongside C-peptide: In insulin-using patients, fasting insulin may reflect injected rather than endogenous insulin; C-peptide specifically isolates the endogenous component.
• Autoantibodies (GAD65, IA-2, ZnT8): Distinguishes autoimmune from non-autoimmune causes of low C-peptide. Why test alongside C-peptide: Positive autoantibodies alongside low C-peptide confirm autoimmune beta cell destruction; negative autoantibodies in the same picture point toward non-autoimmune beta cell exhaustion or a different mechanism.
• hs-CRP: Reflects systemic low-grade inflammation, which is relevant in insulin resistance and in the inflammatory context of autoimmune disease. Why test alongside C-peptide: Elevated hs-CRP alongside low C-peptide adds inflammatory context that may support an autoimmune or metabolic stress hypothesis.

When to Take This Seriously

A low or undetectable C-peptide result warrants clinical evaluation rather than monitoring in isolation. Several specific scenarios deserve prompt attention.

A very low or undetectable fasting C-peptide in someone who has not received an established Type 1 diagnosis — particularly an adult who was diagnosed as Type 2 — should prompt autoantibody testing and specialist review. This pattern may indicate LADA or true Type 1 presenting in adulthood, and the distinction significantly affects treatment decisions.

In established Type 1 diabetes, tracking C-peptide trajectory matters. Lachin and colleagues in 2014 documented that any residual C-peptide secretion is associated with meaningfully better microvascular outcomes. Someone with detectable residual C-peptide may qualify for clinical trials of beta cell preservation therapies that are unavailable to individuals who have already lost all measurable production.

Volpe and colleagues, in a 2021 paper in Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, describe how C-peptide testing helps providers avoid treatment errors: a patient with low C-peptide who is initiated on oral glucose-lowering agents rather than insulin may experience significant undertreatment. Confirming low C-peptide is the biological basis for ensuring appropriate insulin therapy.

For individuals with borderline metabolic findings and no established diabetes, low-end C-peptide values alongside borderline fasting glucose or HbA1c are worth discussing with a provider as part of a structured metabolic workup. Reintar and colleagues in 2023 showed that reduced UCPCR in healthy adults correlates with adverse metabolic risk indicators, suggesting C-peptide provides signal about beta cell reserve before clinical diabetes emerges. Kabytaev, Maddaloni, and Ferm in 2026 emphasize the importance of standardized C-peptide interpretation as the marker's clinical applications continue to expand beyond its traditional classification role.

IMPORTANT SAFETY INFORMATION

This article is for educational and informational purposes only. A low C-peptide result requires interpretation by a qualified healthcare provider in the context of your individual health history, current medications, diabetes history, and other laboratory findings. This content does not constitute medical advice, diagnosis, or treatment recommendations.

C-peptide reference ranges vary by laboratory and assay platform — absolute values can differ between labs. Your provider will interpret your specific result in context.

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Low C-peptide results require interpretation by a qualified healthcare provider in the context of your individual clinical history and other laboratory findings.